Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L29 pseudogene 2 (RPL29P2) is a non-functional pseudogene based on sequence homology to the functional ribosomal protein L29 (RPL29), which encodes a structural constituent of the large (60S) ribosomal subunit[1][2][8][9]. RPL29P2, as a pseudogene, does not produce a functional protein and is not involved in active biological processes or diseases, nor does it serve as a drug target or biomarker. Pseudogenes like RPL29P2 are considered genomic remnants of once-protein-coding genes that usually arise from retrotransposition events[8]. Because RPL29P2 is a pseudogene: - It lacks protein-coding ability and does not participate in cellular signal transduction, metabolism, or regulatory pathways[1][2][8]. - There are no known drugs or therapeutic agents that interact with this pseudogene, nor is it a recognized biomarker or source of safety concerns. - The existence of such pseudogenes can be informative in evolutionary studies and for the annotation of the human genome[8]. - The parent gene RPL29 is involved in ribosomal structure and protein synthesis, but the pseudogene RPL29P2 has no known direct biological or disease role[1][7][8]. There is no evidence or reference to RPL29P2 being misnamed, misspelled, or representing a real protein-coding or therapeutic target. It is correctly annotated and appropriately described as a pseudogene in major genomic resources[1][2][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L29 pseudogene 2 (RPL29P2).